导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 20.94% | 366/4773 |
| 近一周 | 0.13% | 787/5465 |
| 近一月 | -5.84% | 3909/5421 |
| 近一季 | -13.90% | 4207/5231 |
| 近半年 | 19.69% | 218/4920 |
| 近一年 | 26.59% | 296/4394 |
| 近两年 | 152.87% | 227/2954 |
| 近三年 | 96.76% | 183/2253 |
| 成立以来 | 110.98% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.72% 3373/4961 |
63.58% 362/5312 |
- - |
- - |
| 2025 | 59.88% 214/4813 |
2.75% 1276/3635 |
3.40% 1018/4076 |
51.61% 273/4524 |
-0.74% 2623/4813 |
| 2024 | 11.00% 1353/3463 |
-3.35% 1492/2808 |
-5.23% 1675/3014 |
22.61% 460/3129 |
-1.16% 1609/3463 |
| 2023 | -24.10% 1966/2656 |
0.82% 1692/2280 |
-8.01% 1946/2385 |
-10.48% 2001/2515 |
-8.57% 2301/2655 |
| 2022 | -31.63% 1662/2207 |
-18.60% 1358/1919 |
9.34% 286/2016 |
-22.11% 1922/2113 |
-1.37% 1696/2208 |
| 2021 | 7.27% 500/1822 |
-5.85% 962/1255 |
21.90% 129/1330 |
-6.69% 980/1466 |
0.18% 1162/1822 |
| 2020 | 80.77% 40/1250 |
4.38% 74/1028 |
31.08% 43/1067 |
10.86% 503/1164 |
19.19% 81/1184 |
| 2019 | 44.62% 166/1092 |
30.74% 232/754 |
-8.17% 582/804 |
8.26% 66/850 |
11.27% 71/918 |
| 2018 | - - |
- - |
- - |
- - |
-16.68% 640/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华夏战略新兴成指ETF VS. 长安沪深300非周期A(740101) |